small molecule

GELNIQUE

OXYBUTYNIN CHLORIDE

Loss of exclusivityMarch 2031latest FDA-listed patent expiry
CompanyAbbVie Inc.View the full company profile on CliffBio

Drug detail

Brand nameGELNIQUE
Active ingredientOXYBUTYNIN CHLORIDE
Strength10% (100MG/PACKET) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formGEL
RouteTRANSDERMAL
ModalitySmall molecule
FDA approvalJanuary 2009
Marketing statusDISCN

Listed patents

PatentExpiresType
8920392March 2031use U-1644
10449173November 2029product
9259388November 2029use U-1644

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

GELNIQUE patent cliff — loss of exclusivity March 2031 | CliffBio